Laura Carvajal-Galvez

Malaga, AN, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.

Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.

Journal: Frontiers in immunology
Published: April 13, 2026

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors.

The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors.

Journal: Breast (Edinburgh, Scotland)
Published: January 07, 2026

Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial.

Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial.

Journal: Cancers
Published: December 03, 2024

Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.

Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.

Journal: JCO global oncology
Published: March 21, 2024

Hodgkin lymphoma and liquid biopsy: a story to be told.

Hodgkin lymphoma and liquid biopsy: a story to be told.

Journal: Journal of experimental & clinical cancer research : CR
Published: March 12, 2024

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Journal: Frontiers in immunology
Published: September 13, 2023

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 21, 2022

Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma.

Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma.

Journal: Biomedicines
Published: August 26, 2021

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.

Journal: Journal for immunotherapy of cancer
Published: May 08, 2021

Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.

Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.

Journal: International journal of hematology
Published: March 08, 2021

Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.

Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.

Journal: Therapeutic advances in medical oncology
Published: November 19, 2019

Targeted treatment approaches in refractory germ cell tumors.

Targeted treatment approaches in refractory germ cell tumors.

Journal: Critical reviews in oncology/hematology
Published: April 09, 2019
Showing 1-12 of 12

Last Updated: 09/26/2026